Anal intraepithelial neoplasia and anal cancer: Who should be screened?
The association between the human papillomavirus (HPV) and cervical cancer has been well established. Ongoing research and interest have led to the development and improvement of screening methods and preventive vaccines that have effected an overall decrease in incidence rates of cervical cancer, especially in developed countries. In addition, the recently developed prophylactic vaccines against HPV provide the potential benefit of reducing cytologic abnormalities, leading to fewer referrals for colposcopy and excisional procedures.
Key Points
The association between the human papillomavirus (HPV) and cervical cancer has been well established.1 Ongoing research and interest have led to the development and improvement of screening methods and preventive vaccines that have effected an overall decrease in incidence rates of cervical cancer, especially in developed countries.2 In addition, the recently developed prophylactic vaccines against HPV provide the potential benefit of reducing cytologic abnormalities, leading to fewer referrals for colposcopy and excisional procedures.
HPV has also been established as a pathologic factor in the development of multiple other cancers, including cancer of the anus, penis, vulva, vagina, and oropharynx.3 Cancer of the anus has been receiving increased attention over the past few years. Although it is still a relatively rare malignancy compared with cervical cancer, the National Cancer Institute estimates that 6,230 new cases and 780 deaths from anal cancer will occur in the United States in 2012. The rates of anal carcinoma have been steadily increasing for the past 3 decades.4
Incidence
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More
